Published on 24/12/2025
Successful Implementation of Home Health Visits in Clinical Trials: Real-World Examples
Decentralized Clinical Trials (DCTs) are revolutionizing the way studies are conducted, and home health visits play a pivotal role in this transformation. By bringing clinical procedures to the patient’s home, sponsors reduce barriers to participation and improve retention rates. But how does this look in practice? This article explores real-world examples of successful home health visit implementation across therapeutic areas and geographies, providing a roadmap for DCT optimization.
Why Focus on Real-World Success Stories?
While theoretical guidance and SOPs are critical, understanding how leading sponsors operationalize DCTs helps bridge the gap between design and execution. These examples illustrate:
- Operational challenges and solutions
- Patient and investigator feedback
- Regulatory acceptability and documentation standards
- Return on investment and strategic outcomes
Incorporating these insights into your own studies ensures better alignment with GMP compliance and patient-centric goals.
Case Study 1: Oncology Trial in the U.S. Using Hybrid Visits
A Phase 3 oncology trial sponsored by a major U.S. biopharma adopted a hybrid model combining site visits with in-home nurse assessments.
- Procedures moved home: Blood draws, quality of life surveys, ECG monitoring
- Outcome: 22% increase in retention; 95% patient satisfaction
- Technology: Wearable ECG device
Case Study 2: Rare Disease Trial in the EU with Full Home Care
A pediatric rare disease trial required biweekly dosing over 12 months. Home nurse visits were used for all but the screening and final visits.
- Countries involved: UK, Germany, France
- Procedures conducted at home: Infusions, adverse event reporting, vitals, diaries
- Outcome: Reduced screen failure by 17% due to geographic inclusion
- Training: Nurses were trained using materials from Pharma SOP templates translated into local languages
- Retention: 97% completion rate
Case Study 3: COVID-19 Vaccine Trial Incorporating DCT Practices
During the COVID-19 pandemic, a leading sponsor quickly pivoted to home visits to avoid trial disruption.
- Shift: On-site follow-ups moved to telehealth and mobile nurse visits
- Procedures conducted: Swab collection, temperature checks, symptom tracking
- Logistics: Nurses followed a rotating geographic schedule; sample pick-ups aligned with courier services
- Regulatory: EMA approved protocol amendment via fast-track mechanism
- Outcome: Trial completed on time with no COVID-related delays
Key Success Factors from the Case Studies
Analysis of the above trials reveals several shared characteristics of successful home visit execution:
- Early planning: Home visit models were integrated into protocol design, not added later
- Clear SOPs: All case studies used SOPs adapted specifically for home health execution
- Reliable logistics partners: Nurse scheduling, IMP delivery, and sample shipments were well coordinated
- Strong oversight: Monitors conducted regular virtual reviews of source data and home visit logs
- Feedback loops: Ongoing patient and nurse feedback helped refine SOPs and vendor engagement
How Sponsors Measured Success
Sponsors tracked metrics beyond enrollment numbers:
- Visit adherence rates and missed visit frequency
- Patient satisfaction surveys
- Compliance with pharmaceutical regulatory standards
- Data quality from home visits vs. site visits
- Time and cost savings on site operations
Challenges Faced and Overcome
Even successful implementations faced hurdles:
- Nurse variability: Standardized training helped minimize inter-operator differences
- IMP accountability: Sponsors used tamper-evident packaging and delivery confirmations
- Documentation delays: Resolved with real-time eSource tools and mobile apps
- Regulatory ambiguity: Sponsors consulted early with local ethics boards and health authorities
Lessons for Future Home Health Trial Implementations
- Start planning for DCT components during protocol drafting
- Engage cross-functional teams—clinical, logistics, data, and QA
- Leverage prior validation studies for wearable and telemedicine tools
- Align SOPs and vendor processes to GCP expectations
- Monitor not just site performance, but also vendor-led visits
Conclusion
Real-world examples demonstrate that home health visits can deliver powerful results in decentralized and hybrid clinical trials. They improve patient accessibility, maintain protocol fidelity, and deliver data quality comparable to site visits. With proper planning, vendor alignment, and regulatory insight, sponsors can confidently integrate this model into their global development programs. These case studies are a testament to the flexibility, resilience, and future-readiness of modern clinical operations.